Holen Sie sich die Stockscreener-App
4.80
3.21%
-0.18
Schlusskurs vom Vortag:
$4.98
Offen:
$5.04
24-Stunden-Volumen:
596.58K
Relative Volume:
0.58
Marktkapitalisierung:
$351.22M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-2.8402
EPS:
-1.69
Netto-Cashflow:
$-31.03M
1W Leistung:
-2.43%
1M Leistung:
-15.14%
6M Leistung:
+0.63%
1J Leistung:
-39.29%
1-Tages-Spanne:
$4.795
$5.09
1-Wochen-Bereich:
$4.79
$5.295
52-Wochen-Spanne:
$4.25
$9.08
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
4.795 | 364.77M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.84 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.46 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.22 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy - Investing.com
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk - TipRanks
Small cap wrap: 374Water, Ideal Power, Northstar Gold, Candel Therapeutics… - Proactive financial news
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances - Yahoo Finance
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - Bitget
Candel Therapeutics, Inc. announces financial results for the fourth quarter and full year of fiscal 2025, along with recent strategic updates. - Bitget
Tech Rally: Is Candel Therapeutics Inc stock suitable for long term investing2026 Momentum Check & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Candel Therapeutics (NASDAQ:CADL) Raised to Hold at Zacks Research - MarketBeat
Candel Therapeutics Presents New Data From Phase 3 Trial Of Aglatimagene Besadenovec In Localized Prostate Cancer - marketscreener.com
Candel Therapeutics Back On The Radar As Prostate And Lung Cancer Trial Catalysts Approach - RTTNews
Candel Therapeutics to present Phase 3 prostate cancer data at AUA 2026 - Proactive Investors
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - Bitget
Paradigm-shifting prostate cancer trial data to debut at AUA 2026 - Stock Titan
Gainers Report: How Candel Therapeutics Inc. stock compares to market leadersWeekly Market Report & Growth Focused Investment Plans - Naître et grandir
Moving Averages: Will Candel Therapeutics Inc. stock outperform Nasdaq indexJuly 2025 Selloffs & Smart Allocation Stock Tips - Naître et grandir
Candel Therapeutics (CADL) Projected to Post Earnings on Thursday - MarketBeat
Candel Therapeutics, Inc. showcases linoserpaturev immunotherapy progress in recurrent glioblastoma case - Traders Union
United StatesGoodwin Guides Candel Therapeutics On $100 Million Public Offering And $100 Millon Royalty Funding Agreement With RTW - Mondaq
CADL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Candel Therapeutics CEO to present progress on immunotherapies at TD Cowen Health Care Conference - Traders Union
New Candel Therapeutics hire gets 20,000 stock options at $5.25 - Stock Titan
CADL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Hedge Fund and Insider Trading News: David Tepper, Steve Cohen, Ray Dalio, Brevan Howard, Millennium Management, Citadel Investment Group, Candel Therapeutics Inc (CADL), Meta Platforms Inc (META), and More - Insider Monkey
Candel Therapeutics Insider Bought Shares Worth $2,999,996, According to a Recent SEC Filing - marketscreener.com
Paul Manning buys Candel Therapeutics (CADL) shares worth $3m - Investing.com
Paul Manning buys Candel Therapeutics (CADL) shares worth $3m By Investing.com - Investing.com Australia
Candel Therapeutics (NASDAQ:CADL) Director Paul Manning Purchases 550,458 Shares - MarketBeat
Director Paul B. Manning adds 550,458 Candel (NASDAQ: CADL) shares via revocable trust - Stock Titan
Candel Therapeutics, Inc. (CADL) Stock Analysis: Unveiling a 259% Potential Upside in Biotech - DirectorsTalk Interviews
Candel Therapeutics, Inc. unveils science behind CAN-2409 driving durable tumor immune response - Traders Union
Candel Therapeutics CEO to present at TD Cowen health care conference on March 3 - Proactive financial news
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston - Bitget
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston - The Manila Times
Candel Therapeutics CEO to speak at TD Cowen Boston conference - Stock Titan
Candel Therapeutics Announces Equity Offering to Fund CAN-2409 - TipRanks
Candel Therapeutics Prices 18.35M-Share Offering at $5.45, Expects ~$93.5M Net Proceeds - TradingView
Candel Therapeutics (NASDAQ: CADL) prices $100M common stock sale - Stock Titan
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Candel Therapeutics Faces Strategic Financial Moves Amidst Stock Offering - timothysykes.com
Candel Therapeutics Prices $100M Public Offering - Intellectia AI
Candel Therapeutics Faces Market Reaction Post-Secondary Offering - StocksToTrade
Candel Therapeutics’ Stock Offering Sees Market Reaction - timothysykes.com
Candel Therapeutics Prices $100 Million Share Offering - Intellectia AI
Candel Therapeutics Faces Mixed Sentiments After Secondary Offering Announcement - StocksToTrade
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Candel Therapeutics files for offering of 18.3 mln shares of common stock - marketscreener.com
Candel Therapeutics Files For Offering Of 18.3 Mln Shares Of Common Stock - TradingView
Should I hold or sell Candel Therapeutics Inc. nowJuly 2025 Action & Risk Controlled Swing Alerts - mfd.ru
Latham & Watkins Advises RTW Investments on US$100 Million Royalty Funding Agreement With Candel Therapeutics - Latham & Watkins LLP
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):